Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fexofenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | DRD3 | P35462 | 3/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | CNR1 | P21554 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 2/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.96 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.79 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.79 |
| ▸ | GMNN | O75496 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fexofenadine SCHEMBL9943442 | 1.00 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1395675 | 1.00 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL9943444 | 1.00 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1395627 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL48729 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL3178320 | 0.99 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1972366 | 0.99 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1561082 | 0.99 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL4901 | 0.99 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL7104316 | 0.99 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129401-A1 | PROCESSES FOR PREPARING ANHYDROUS AND HYDRATE FORMS OF ANTIHISTAMINIC PIPERIDINE DERIVATIVES, POLYMORPHS AND PSEUDOMORPHS THEREOF | AVENTIS PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | claimed |
| US-20050090528-A1 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof | AVENTIS PHARMACETICALS, INC. | 2005-04-28 | — | — | US | claimed |
| US-20030045722-A1 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof | HENTON DANIEL R (US) | 2003-03-06 | — | — | US | claimed |
| CN-106806346-B | Fexofenadine hydrochloride dry suspension preparation and preparation method thereof | 国药集团广东环球制药有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-106806346-A | A kind of fexofenadine hydrochloride dry suspensoid agent preparation and preparation method thereof | 国药集团广东环球制药有限公司 | 2017-06-09 | — | — | CN | disclosed |
| EP-2289878-A1 | Fexofenadine polymorphs and process for the preparation thereof | Dipharma S.p.A. (IT) | 2011-03-02 | — | — | EP | disclosed |
| WO-2007110884-A3 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE ANHYDROUS FEXOFENADINE HYDROCHLORIDE | IND SWIFT LAB LTD (IN) | 2009-05-28 | — | — | WO | disclosed |
| US-20090111853-A1 | FEXOFENADINE POLYMORPHS AND PROCESS FOR THE PREPARATION THEREOF | DIPHARMA S.P.A. (IT) | 2009-04-30 | — | — | US | disclosed |
| WO-2007110884-A2 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE ANHYDROUS FEXOFENADINE HYDROCHLORIDE | IND-SWIFT LABORATORIES LIMITED (IN) | 2007-10-04 | — | — | WO | disclosed |
| US-20070129401-A1 | PROCESSES FOR PREPARING ANHYDROUS AND HYDRATE FORMS OF ANTIHISTAMINIC PIPERIDINE DERIVATIVES, POLYMORPHS AND PSEUDOMORPHS THEREOF | AVENTIS PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| EP-1614681-A1 | Fexofenadine polymorphs and process for the preparation thereof | Dipharma S.p.A. (IT) | 2006-01-11 | — | — | EP | disclosed |
| US-20050282860-A1 | Fexofenadine polymorphs and process for the preparation thereof | DIPHARMA S.P.A. (IT) | 2005-12-22 | — | — | US | disclosed |
| US-20050090528-A1 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof | AVENTIS PHARMACETICALS, INC. | 2005-04-28 | — | — | US | disclosed |
| EP-1399422-A2 | NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINYL] -1-HYDROXYBUTYL] -A,A-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2004-03-24 | — | — | EP | disclosed |
| US-20030045722-A1 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof | HENTON DANIEL R (US) | 2003-03-06 | — | — | US | disclosed |
| WO-2002102777-A2 | NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282860-A1 | Fexofenadine polymorphs and process for the preparation thereof | CYP4F3, CYP4F2, CYP2C19 | HRH1 27/4885KCNH2 739/4885LMNA 3993/4885 |
| US-20090111853-A1 | FEXOFENADINE POLYMORPHS AND PROCESS FOR THE PREPARATION THEREOF | CYP4F3, CYP4F2, CYP2C19 | HRH1 27/4885KCNH2 739/4885LMNA 3993/4885 |
| US-20050090528-A1 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof | HRH1, HRH2, HRH4 | HRH1 1/4885KCNH2 89/4885LMNA 3956/4885 |
| US-20070129401-A1 | PROCESSES FOR PREPARING ANHYDROUS AND HYDRATE FORMS OF ANTIHISTAMINIC PIPERIDINE DERIVATIVES, POLYMORPHS AND PSEUDOMORPHS THEREOF | HRH1, HRH2, HRH4 | HRH1 1/4885KCNH2 89/4885LMNA 3956/4885 |
| US-20030045722-A1 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof | HRH1, HRH2, HRH4 | HRH1 1/4885KCNH2 123/4885LMNA 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.